Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - glucosamini sulfas natrii chloridum - jauhe oraaliliuosta varten - 1.5 g - glukosamiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft hylkääminen - immunosuppressantit - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopan unioni - suomi - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Suomi - suomi - Ecolab

ecolab deutschland gmbh -

Suomi - suomi - Fimea (Suomen lääkevirasto)

aspen pharma trading limited - digoxin - tabletti - 0.0625 mg - digoksiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

aspen pharma trading limited - digoxin - tabletti - 0.125 mg - digoksiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

aspen pharma trading limited - digoxin - tabletti - 0.25 mg - digoksiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 25 mg - atsatiopriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 50 mg - atsatiopriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

2care4 generics aps - mercaptopurine monohydrate - tabletti - 50 mg - merkaptopuriini